Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 3/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255645 | 0.86 | S1PR4 (0.37) | S1PR4S1PR1S1PR3S1PR5GRM4 | |
| SCHEMBL20843659 | 0.86 | S1PR4 (0.37) | S1PR4S1PR1S1PR3S1PR5GRM4 | |
| SCHEMBL18207894 | 0.77 | — | — | |
| SCHEMBL2700252 | 0.73 | S1PR4 (0.40) | S1PR4S1PR1S1PR3S1PR5MMP8 | |
| SCHEMBL3481359 | 0.72 | — | — | |
| SCHEMBL19212002 | 0.72 | S1PR4 (0.42) | S1PR4S1PR1S1PR3S1PR5GRM4 | |
| SCHEMBL23459226 | 0.70 | GRM4 (0.38) | S1PR4S1PR1S1PR3ALDH1A1GRM4 | |
| SCHEMBL7042044 | 0.70 | S1PR4 (0.53) | S1PR4S1PR1S1PR3S1PR5MMP8 | |
| SCHEMBL14743862 | 0.70 | S1PR4 (0.38) | S1PR4S1PR1S1PR3S1PR5GRM4 | |
| SCHEMBL585039 | 0.69 | MMP2 (0.41) | S1PR4S1PR1S1PR3S1PR5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | NEWTHERA (FR) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209474-A1 | NOVEL USES FOR DRUGS TARGETING GLUTAMINE SYNTHETASE | GLUL, GLS2, ASNS | S1PR4 3169/4885S1PR1 2697/4885S1PR3 2693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.